Search results
Results from the WOW.Com Content Network
In a statement on Friday, the two partners said Jardiance cut the risk of kidney disease progression and cardiovascular death by 28%, citing results from a late-stage trial which included people ...
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . [5] [6] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).
In the United States, empagliflozin is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure; [12] to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression; [12] to reduce the risk of cardiovascular death in ...
Kidney toxicity [5] associated with kidney failure; associated with development of cancer, particularly of the urinary tract, known carcinogen [8] [9] Atractylate Atractylis gummifera: Liver damage, [3] nausea, vomiting, epigastric and abdominal pain, diarrhoea, anxiety, headache and convulsions, often followed by coma [10]
SGLT2 is only found in kidney tubules and in conjunction with SGLT1 resorbs glucose into the blood from the forming urine. By inhibiting SGLT2, and not targeting SGLT1, glucose is excreted which in turn lowers blood glucose levels. Examples include dapagliflozin (Farxiga in US, Forxiga in EU), canagliflozin (Invokana) and empagliflozin (Jardiance).
The AASK trial showed that ACEis are more effective at slowing down the decline of kidney function compared to calcium channel blockers and beta blockers. [16] As such, ACEis should be the drug treatment of choice for patients with chronic kidney disease regardless of race or diabetic status. [7]
Just Words. If you love Scrabble, you'll love the wonderful word game fun of Just Words. Play Just Words free online! By Masque Publishing
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.